The European Pharmaceutical Review (EPR), a leading Pharma publication, has published Freyr’s expert opinion on China and it’s evolving Regulatory landscape. Decode exclusive insights on the regional Regulatory transformation, the NMPA reforms, and their impact on the Chinese market-entry.

Click here to read the complete "European Pharmaceutical Review" Issue.